Scrip's Five Must-Know Things - Sept, 14, 2026

Audio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 11, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—what’s next in cardiovascular R&D following recent Phase III failures; sequential gains for nine of the world’s 10 best-selling drugs in Q2; AstraZeneca’s first-in-class COPD contender out-performs Dupixent in Phase III trial; Renexxion’s co-founder explains why naronapride can succeed in gastroparesis; and Chinese companies expand global Phase III activity.  Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-G5UM7ATTY5E3DAD6X7NW2OI4EA/ This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Contact us on [email protected].